Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Other analysts have also recently issued research reports about the stock. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Trading Up 1.2 %

Shares of CTSO opened at $0.91 on Tuesday. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $2.15. The company has a 50 day simple moving average of $1.10 and a two-hundred day simple moving average of $1.01. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a market cap of $49.77 million, a P/E ratio of -2.61 and a beta of 0.56.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the 3rd quarter valued at about $51,000. Geode Capital Management LLC raised its position in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. CM Management LLC lifted its stake in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Sargent Investment Group LLC boosted its holdings in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares during the period. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.